GlobeNewswire: Microbot Medical Contains the last 10 of 91 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:02:08ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/12/27/2358013/0/en/Microbot-Medical-Announces-Strategic-Collaboration-with-Stryker-Corporation-to-Develop-the-LIBERTY-Robotic-System-for-Neurovascular-Applications.html?f=22&fvtc=4&fvtv=30685Microbot Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY® Robotic System for Neurovascular Applications2021-12-27T12:05:00Z<![CDATA[HINGHAM, Mass., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures.]]>https://www.globenewswire.com/news-release/2021/12/23/2357375/0/en/Microbot-Medical-Secures-Third-Patent-for-the-LIBERTY-Robotic-System-in-the-United-States-Success-of-Protecting-Novel-Intellectual-Property-Complements-Recent-Design-Freeze-Achieve.html?f=22&fvtc=4&fvtv=30685Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States; Success of Protecting Novel Intellectual Property Complements Recent Design Freeze Achievement2021-12-23T13:15:00Z<![CDATA[HINGHAM, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a third patent application covering the Company’s LIBERTY® Robotic System. The Company has secured all three U.S. patents during 2021. Globally, the Company now has 47 patents issued/allowed and 26 pending patent applications and is continuously submitting applications to protect its Intellectual Property.]]>https://www.globenewswire.com/news-release/2021/12/22/2357050/0/en/Microbot-Medical-Initiates-Search-for-U-S-Clinical-Sites-for-the-LIBERTY-Robotic-System.html?f=22&fvtc=4&fvtv=30685Microbot Medical Initiates Search for U.S. Clinical Sites for the LIBERTY® Robotic System2021-12-22T21:05:00Z<![CDATA[HINGHAM, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY® Robotic System for commercialization. In conjunction with recently announced design freeze, Dr. Eyal Morag, Microbot’s Chief Medical Officer, traveled to the United States to establish a clinical infrastructure with multiple sites and leading physicians for the commencement of a human clinical trial, which is expected to commence in the second half of 2022.]]>https://www.globenewswire.com/news-release/2021/12/15/2352527/0/en/Microbot-Medical-Achieves-Design-Freeze-of-the-LIBERTY-Robotic-System-Meets-Previously-Stated-Milestone-Timeline.html?f=22&fvtc=4&fvtv=30685Microbot Medical Achieves Design Freeze of the LIBERTY® Robotic System; Meets Previously Stated Milestone Timeline2021-12-15T12:30:00Z<![CDATA[Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA]]>https://www.globenewswire.com/news-release/2021/11/19/2338140/0/en/Microbot-Medical-Secures-Additional-Patent-for-the-LIBERTY-Robotic-System-in-the-United-States.html?f=22&fvtc=4&fvtv=30685Microbot Medical Secures Additional Patent for the LIBERTY® Robotic System in the United States2021-11-19T12:00:00Z<![CDATA[HINGHAM, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Company’s LIBERTY® Robotic System. Globally, the Company now has 46 patents issued/allowed and 24 pending patent applications and is continuously submitting applications to protect its Intellectual Property.]]>https://www.globenewswire.com/news-release/2021/10/06/2309435/0/en/Microbot-Medical-Secures-Patent-for-LIBERTY-Robotic-System-in-the-United-States.html?f=22&fvtc=4&fvtv=30685Microbot Medical Secures Patent for LIBERTY® Robotic System in the United States2021-10-06T11:00:00Z<![CDATA[HINGHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance covering the Company’s LIBERTY® Robotic System. Globally, the Company now has 45 patents issued/allowed and 24 pending patent applications.]]>https://www.globenewswire.com/news-release/2021/06/29/2254588/0/en/Microbot-Medical-Secures-Patent-Allowance-in-China-Third-Global-Jurisdiction-in-2021-to-Recognize-Novelty-of-One-Done-Technology.html?f=22&fvtc=4&fvtv=30685Microbot Medical Secures Patent Allowance in China; Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology 2021-06-29T11:00:00Z<![CDATA[HINGHAM, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that China has become the latest global jurisdiction to issue a Notice of Allowance (NOA) for the Company’s innovative ‘One & Done’ guidewire technology, joining the European Union along with those received earlier this year from Japan and Israel. Globally, the Company now holds a total of 44 patents issued/allowed and 24 pending patent applications.]]>https://www.globenewswire.com/news-release/2021/06/07/2242595/0/en/Leading-Interventional-Cardiologist-Dr-Giora-Weisz-Joins-Microbot-Medical-s-Scientific-Advisory-Board.html?f=22&fvtc=4&fvtv=30685Leading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical’s Scientific Advisory Board2021-06-07T11:00:00Z<![CDATA[HINGHAM, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Company’s Scientific Advisory Board (SAB). Dr. Weisz is a practicing interventional cardiologist and clinical researcher who has pioneered novel robotic-enhanced coronary interventions, as well as navigation and positioning technologies. His areas of expertise include cardiac catheterization, coronary artery disease and diagnostic angiography, which make his assistance an invaluable asset to Microbot as it continues to develop the LIBERTY™ Robotic System.]]>https://www.globenewswire.com/news-release/2021/06/04/2241946/0/en/Microbot-Medical-Secures-Additional-Protection-for-the-One-Done-Guidewire-Technology-with-another-Notice-of-Patent-Allowance.html?f=22&fvtc=4&fvtv=30685Microbot Medical Secures Additional Protection for the One & Done Guidewire Technology with another Notice of Patent Allowance2021-06-04T11:00:00Z<![CDATA[HINGHAM, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Global patent jurisdictions continue to recognize Microbot Medical Inc.’s (Nasdaq: MBOT) innovative ‘One & Done’ guidewire technology, as the Israel Intellectual Property Office has issued a Notice of Allowance (NOA). The allowed application covers Microbot’s double guidewire technology that has been granted in Europe, Japan and now Israel. Globally, Microbot Medical holds a total of 42 patents issued/allowed and 23 pending patent applications.]]>https://www.globenewswire.com/news-release/2021/02/04/2169783/0/en/Microbot-Medical-Granted-Patent-Allowance-in-Japan-Global-Jurisdictions-Recognizing-Novel-One-Done-Technology.html?f=22&fvtc=4&fvtv=30685Microbot Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel ‘One & Done’ Technology2021-02-04T12:00:00Z<![CDATA[HINGHAM, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal interventions. Japan is the second jurisdiction to grant a patent for the ‘One & Done’ guidewire technology and further protects the novel technology the Company is currently developing.]]>